Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Target Price of $43.93 According to Analysts

Shares of Qiagen N.V. (NYSE:QGEN) have received an average rating of “Hold” from the fourteen analysts that are covering the firm, Marketbeat.com reports. Ten analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $44.43.

QGEN has been the topic of several recent research reports. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a report on Friday, August 7th. TD Cowen reissued a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Barclays set a $40.00 target price on shares of Qiagen and gave the company an “equal weight” rating in a research report on Friday, August 7th. Citigroup reaffirmed a “neutral” rating and issued a $45.00 price target (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Finally, Weiss Ratings raised Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 11th.

Qiagen Stock Up 0.4%

Shares of QGEN stock opened at $50.42 on Wednesday. Qiagen has a fifty-two week low of $32.53 and a fifty-two week high of $57.81. The firm has a market capitalization of $10.39 billion, a PE ratio of 20.73, a P/E/G ratio of 4.99 and a beta of 0.61. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The stock’s 50-day simple moving average is $44.44 and its 200-day simple moving average is $40.64.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The firm had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities analysts expect that Qiagen will post 2.44 earnings per share for the current year.

Institutional Trading of Qiagen

A number of hedge funds have recently added to or reduced their stakes in QGEN. Assenagon Asset Management S.A. boosted its stake in shares of Qiagen by 1.9% during the third quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock worth $691,000 after buying an additional 286 shares during the period. Allworth Financial LP grew its position in Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after buying an additional 317 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after buying an additional 876 shares during the last quarter. Quadrant Capital Group LLC increased its stake in Qiagen by 2.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 42,660 shares of the company’s stock valued at $1,938,000 after buying an additional 1,003 shares during the period. Finally, Hilltop National Bank acquired a new position in Qiagen in the 2nd quarter valued at $50,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.